| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CNCR.29460 |
| P698 | PubMed publication ID | 26043235 |
| P50 | author | Filip Janku | Q73569186 |
| P2093 | author name string | Daniel D Karp | |
| Patrick A Singleton | |||
| Jonathan Moss | |||
| Johnique T Atkins | |||
| P2860 | cites work | Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis | Q24323164 |
| The basics of epithelial-mesenchymal transition | Q24652992 | ||
| Epithelial to mesenchymal transition: the doorway to metastasis in human lung cancers | Q84772564 | ||
| The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer | Q28541351 | ||
| Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors | Q33702325 | ||
| Increased μ-opioid receptor expression in metastatic lung cancer | Q33951500 | ||
| Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer | Q33951506 | ||
| The effect of anesthetic technique on survival in human cancers: a meta-analysis of retrospective and prospective studies | Q34598889 | ||
| A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection | Q35000444 | ||
| Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer | Q35011905 | ||
| The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation | Q35083162 | ||
| Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? | Q35098214 | ||
| μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer | Q35846683 | ||
| Development of peripheral opioid antagonists' new insights into opioid effects | Q37284076 | ||
| A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability | Q37582266 | ||
| Epithelial-mesenchymal transition in cancer development and its clinical significance | Q37644546 | ||
| Effect of anaesthetic technique and other perioperative factors on cancer recurrence | Q37772357 | ||
| The μ-opioid receptor in cancer progression: is there a direct effect? | Q37987336 | ||
| OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis | Q38104745 | ||
| Challenges for opioid receptor nomenclature: IUPHAR Review 9. | Q38188055 | ||
| Association of mu-opioid receptor expression with lymph node metastasis in esophageal squamous cell carcinoma | Q39034167 | ||
| Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis | Q39395019 | ||
| A long-term survey of morphine in cancer pain patients | Q39500877 | ||
| Endogenous μ-opioid peptides modulate immune response towards malignant melanoma | Q39826592 | ||
| Effect of Perioperative Opioids on Cancer Recurrence: A Hypothesis | Q39843460 | ||
| Cancer recurrence after surgery: a role for regional anesthesia? | Q42848002 | ||
| Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats | Q43683101 | ||
| Opioid antagonists inhibit the growth of metastatic murine neuroblastoma | Q44331007 | ||
| Polymorphism of A118G in μ-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population | Q44334859 | ||
| Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: a retrospective analysis | Q44345816 | ||
| Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck | Q44350786 | ||
| Consensus statement from the BJA Workshop on Cancer and Anaesthesia | Q47832518 | ||
| Surgery for cancer: does anesthesia matter? | Q48355950 | ||
| Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence | Q48371016 | ||
| Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia | Q48483803 | ||
| Combined spinal and general anesthesia attenuates liver metastasis by preserving TH1/TH2 cytokine balance | Q48617847 | ||
| Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. | Q52578077 | ||
| Naltrexone modulates tumor response in mice with neuroblastoma | Q71778547 | ||
| Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival | Q78290738 | ||
| Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation | Q79837987 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2681-2688 | |
| P577 | publication date | 2015-06-04 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | The mu opioid receptor: A new target for cancer therapy? | |
| P478 | volume | 121 |
| Q39132056 | A systematic review of the impact of pain on overall survival in patients with cancer |
| Q92750018 | Design, synthesis and evaluation of 111In labeled DOTA-conjugated tetrapeptides having high affinity and selectivity for mu opioid receptors |
| Q94571931 | Dezocine regulates the malignant potential and aerobic glycolysis of liver cancer targeting Akt1/GSK-3β pathway |
| Q58613610 | Epidural anesthesia and cancer outcomes in bladder cancer patients: is it the technique or the medication? A matched-cohort analysis from a tertiary referral center |
| Q48112418 | Impact of opioid use on health care utilization and survival in patients with newly diagnosed stage IV malignancies. |
| Q40052118 | Intraoperative Fentanyl Consumption Does Not Impact Cancer Recurrence or Overall Survival after Curative Colorectal Cancer Resection. |
| Q33834080 | Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance. |
| Q92705573 | Mu Opioid Receptor 1 (MOR-1) Expression in Colorectal Cancer and Oncological Long-Term Outcomes: A Five-Year Retrospective Longitudinal Cohort Study |
| Q64101215 | Optimal treatment of opioid induced constipation in daily clinical practice - an observational study |
| Q47136932 | Role of Dopamine Receptors in the Anticancer Activity of ONC201. |
| Q39155149 | Spinal Metastatic Disease: A Review of the Role of the Multidisciplinary Team |
| Q90635852 | The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety |
| Q36200195 | The association between different opioid doses and the survival of advanced cancer patients receiving palliative care |
| Q104607423 | The association of prescription opioid use with incident cancer: A surveillance, epidemiology, and end results-medicare population-based case-control study |
| Q90364854 | The effect of epidural analgesia on cancer progression in patients with stage IV colorectal cancer after primary tumor resection: A retrospective cohort study |
| Q89970109 | The impact of pain and opioids use on survival in cancer patients: Results from a population-based cohort study and a meta-analysis |
| Q39442254 | Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer |
Search more.